Ravichandran Venkataramani
Nessuna posizione attualmente
Profilo
Ravichandran Venkataramani was the founder of Vtesse, Inc. which was founded in 2015, where he held the title of Chief Business Officer.
He also held the position of Vice President-Business Development at Genocea Biosciences, Inc. Dr. Venkataramani obtained a doctorate degree from the University of Pennsylvania and an undergraduate degree from the University of Wisconsin.
Precedenti posizioni note di Ravichandran Venkataramani
Società | Posizione | Fine |
---|---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Fondatore | - |
GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Formazione di Ravichandran Venkataramani
University of Wisconsin | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Ravichandran Venkataramani